Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment
Information source: Université de Sherbrooke
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cerebral Metastases
Phase: N/A
Status: Completed
Sponsored by: Martin Lepage Official(s) and/or principal investigator(s): Jean Chenard, MD, Principal Investigator, Affiliation: University of Sherbrooke
Summary
Hypothesis: the pattern of MRI contrast enhancement after gadolinium injection is different
in tumors that respond well to gamma knife.
We are going to acquire sequential T1-weighted images of brain lesions before, during and
after injection of Gd-DTPA. This will be repeated before and after a treatment with gamma
knife. We will then analyse our results to see if there are common enhancement
characteristics between lesions that will respond well to the radiosurgery treatment.
Response will be clinically assessed by tumor volume as determined by MRI approximately 4 to
6 months after treatment.
Clinical Details
Official title: Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: MRI parameters
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient with intracerebral lesion benign or malignant wich are not concerned by the
exclusion criteria
Exclusion Criteria:
- Pancranial radiotherapy
- Residual postop lesion
- Gliomas
- Patients < 18 years old
- Anterior allergic reaction to gadolinium
- Claustrophobia.
Locations and Contacts
Faculté de médecine, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada
Additional Information
Starting date: August 2005
Last updated: January 13, 2015
|